Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
Colon/Rectal Cancer
Lung Cancer
Solid Tumor
18 - 100 Years, Male and Female
EGFR-008-001 (primary)
NCI-2023-02676
Summary
This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation
and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK),
pharmacodynamics (PD), and preliminary anti-tumor activity of JANX008 in adult subjects
with advanced or metastatic carcinoma expressing EGFR.
Eligibility
- Subjects =18 years of age at the time of signing informed consent
- Histologically or cytologically documented locally advanced or metastatic NSCLC, SCCHN, CRC, RCC, SCLC, PDAC, TNBC
- Progressed or was intolerant to all available therapies known to confer clinical benefit appropriate for the tumor type
- Adequate organ function
- At least 1 measurable lesion per RECIST 1.1
Treatment Sites in Georgia
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials.